National Registry of rFVIIa (Novoseven) in Haemorrhagic Traumatology
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 200
Summary
- Conditions
- Bleeding
- Hemorrhage
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
It consists of a study of a prospective cohort in 36 centers, for 3 years, from April 1st 2008. The data of all patients who received rFVIIa in traumatic situation were collected. The investigators colligated clinical and biological parameters; have been analyzed treatment received during initial ca...
It consists of a study of a prospective cohort in 36 centers, for 3 years, from April 1st 2008. The data of all patients who received rFVIIa in traumatic situation were collected. The investigators colligated clinical and biological parameters; have been analyzed treatment received during initial care, in intensive care before and after they received rFVIIa, length of stay in ICU, secondary effects, complications and patients outcome. ISS and TRISS score were calculated to predict mortality.
Tracking Information
- NCT #
- NCT01532661
- Collaborators
- Novo Nordisk A/S
- Société Française d'Anesthésie et de Réanimation
- Investigators
- Principal Investigator: PAYEN JF, MD University Hospital, Grenoble
Get Well Soon